These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16880646)

  • 1. Evaluation of the disintegration properties of commercial famotidine 20 mg orally disintegrating tablets using a simple new test and human sensory test.
    Harada T; Narazaki R; Nagira S; Ohwaki T; Aoki S; Iwamoto K
    Chem Pharm Bull (Tokyo); 2006 Aug; 54(8):1072-5. PubMed ID: 16880646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new method for disintegration studies of rapid disintegrating tablet.
    Narazaki R; Harada T; Takami N; Kato Y; Ohwaki T
    Chem Pharm Bull (Tokyo); 2004 Jun; 52(6):704-7. PubMed ID: 15187391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a new disintegration method for orally disintegrating tablets.
    Kakutani R; Muro H; Makino T
    Chem Pharm Bull (Tokyo); 2010 Jul; 58(7):885-90. PubMed ID: 20606331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a novel and simple method to evaluate disintegration of rapidly disintegrating tablets.
    Hoashi Y; Tozuka Y; Takeuchi H
    Chem Pharm Bull (Tokyo); 2013; 61(9):962-6. PubMed ID: 23995360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new modified wetting test and an alternative disintegration test for orally disintegrating tablets.
    Hooper P; Lasher J; Alexander KS; Baki G
    J Pharm Biomed Anal; 2016 Feb; 120():391-6. PubMed ID: 26774944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical disintegration time of orally disintegrating tablets clinically available in Japan in healthy volunteers.
    Yoshita T; Uchida S; Namiki N
    Biol Pharm Bull; 2013; 36(9):1488-93. PubMed ID: 23995661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the palatabilities in 10 different famotidine orally disintegrating tablets by combination of disintegration device and taste sensor.
    Yoshida M; Hazekawa M; Haraguchi T; Uchida T
    Drug Dev Ind Pharm; 2015; 41(8):1387-92. PubMed ID: 25196898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of active ingredients on the swelling properties of orally disintegrating tablets prepared by microwave treatment.
    Sano S; Iwao Y; Kimura S; Noguchi S; Itai S
    Int J Pharm; 2014 Jul; 468(1-2):234-42. PubMed ID: 24709215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection of generic preparations of famotidine orally disintegrating tablets for use in unit-dose packages.
    Yamazaki N; Iizuka R; Miyazawa S; Wada Y; Shimokawa K; Ishii F
    Drug Discov Ther; 2012 Oct; 6(5):263-8. PubMed ID: 23229147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of co-processed excipients used for direct compression of orally disintegrating tablets (ODT) using novel disintegration apparatus.
    Brniak W; Jachowicz R; Krupa A; Skorka T; Niwinski K
    Pharm Dev Technol; 2013; 18(2):464-74. PubMed ID: 22881600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of a new disintegration test system for the evaluation of orally disintegrating films.
    Takeuchi Y; Kawamoto M; Tahara K; Takeuchi H
    Int J Pharm; 2018 Dec; 553(1-2):281-289. PubMed ID: 30366069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of disintegration of rapidly disintegrating tablets by a visiometric liquid jet-mediated disintegration apparatus.
    Desai PM; Liew CV; Heng PW
    Int J Pharm; 2013 Feb; 442(1-2):65-73. PubMed ID: 22985772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of palatability of 10 commercial amlodipine orally disintegrating tablets by gustatory sensation testing, OD-mate as a new disintegration apparatus and the artificial taste sensor.
    Uchida T; Yoshida M; Hazekawa M; Haraguchi T; Furuno H; Teraoka M; Ikezaki H
    J Pharm Pharmacol; 2013 Sep; 65(9):1312-20. PubMed ID: 23927469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of the in vitro disintegration profile of rapidly disintegrating tablets and correlation with oral disintegration.
    Abdelbary G; Eouani C; Prinderre P; Joachim J; Reynier J; Piccerelle P
    Int J Pharm; 2005 Mar; 292(1-2):29-41. PubMed ID: 15725551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation design of an oral, fast-disintegrating dosage form containing taste-masked particles of famotidine.
    Mizumoto T; Tamura T; Kawai H; Kajiyama A; Itai S
    Chem Pharm Bull (Tokyo); 2008 Jul; 56(7):946-50. PubMed ID: 18591807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conceptualisation, Development, Fabrication and In Vivo Validation of a Novel Disintegration Tester for Orally Disintegrating Tablets.
    Koner JS; Rajabi-Siahboomi AR; Missaghi S; Kirby D; Perrie Y; Ahmed J; Mohammed AR
    Sci Rep; 2019 Aug; 9(1):12467. PubMed ID: 31462654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of disintegration properties of orally rapidly disintegrating tablets using a novel disintegration tester.
    Kondo K; Niwa T; Danjo K
    Chem Pharm Bull (Tokyo); 2012; 60(10):1240-8. PubMed ID: 23036967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative evaluation of the disintegration of orally rapid disintegrating tablets by X-ray computed tomography.
    Otsuka M; Yamanaka A; Uchino T; Otsuka K; Sadamoto K; Ohshima H
    Chem Pharm Bull (Tokyo); 2012; 60(12):1502-7. PubMed ID: 23006519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taste masking microspheres for orally disintegrating tablets.
    Xu J; Bovet LL; Zhao K
    Int J Pharm; 2008 Jul; 359(1-2):63-9. PubMed ID: 18455893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A New Approach to Enhance the Solubility of Famotidine Tablet by Using Naturally Isolated Pear Starch.
    Anjali K; Manjul SP
    Recent Pat Drug Deliv Formul; 2018; 12(1):75-80. PubMed ID: 29303081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.